Vitruvias Therapeutics, Inc Issues Nationwide Recall of One Lot of Thyroid Tablets, USP 30 mg Due to Potential Super Potency
AUBURN, Ala. (August 21, 2026) – Vitruvias Therapeutics, Inc. is voluntarily recalling one lot (Lot....
Publisher
USA
This page provides a limited summary, publisher metadata, and related coverage to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- FDA MedWatch
- Region
- USA
- Scope
- Regulatory
- Published
- August 24, 2026
- Language
- EN
Publisher context, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
AUBURN, Ala. (August 21, 2026) – Vitruvias Therapeutics, Inc. is voluntarily recalling one lot (Lot....
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA MedWatch
Scope: Regulatory
Related coverage